TCT 2017

ABSORB III: after 3 Years, the Bioresorbable Scaffold is Still a Disappointment

Courtesy of the SBHCI. The 3-year outcomes of the ABSORB III trial, which randomized 2008 patients 2:1 to...

Absorb IV: Bioresorbable Scaffolds with an Optimized Implantation Technique

 Courtesy of the SBHCI. The Absorb IV trial randomized 2604 patients in a 1:1 ratio to receive an Absorb everolimus-eluting...

ABSORB II: No Benefits from Scaffolds After Complete Bioresorption

 Courtesy of the SBHCI. The ABSORB II study sought to assess the mechanical properties of everolimus-eluting bioresorbable scaffolds, such...

DKCRUSH-V: What Is Simple Is Not Always Best for the Left Main Coronary Artery

Courtesy of the SBHCI. Angioplasty of true distal left main bifurcation lesions with a double-kissing (DK) crush two-stent...

EXCEL-QOL Substudy: Similar Quality of Life both with CABG and Left Main PCI

Courtesy of SBHCI. According to a new quality of life sub-study, the “EXCEL”, both coronary artery bypass graft and...

HREVS: Hybrid Revascularization Offers No Advantage in Multivessel Disease

Courtesy of SBHCI. Hybrid revascularization, which combines CABG with PCI, failed to reduce myocardial ischemia and major cardiac...

CULPRIT-SHOCK Results Will Transform Guidelines and Clinical Practice

 Courtesy of the SBHCI. After treating the culprit lesion in patients with acute myocardial infarction complicated by cardiogenic...

DARE: Drug-Coated Balloons Compete with DES for the Treatment of In-Stent Restenosis

Courtesy of the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI). The SeQuent Please paclitaxel-coated balloon provides non-inferior...